A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Inclusion Criteria:

- Subjects must meet one of the following:

- Treatment-naive: Subject has never received antiviral treatment for hepatitis C
infection OR

- Treatment Experienced (Prior null responders, Partial responders or Relapsers to
pegIFN/RBV);

- Body mass index (BMI) is ≥ 18 to < 38 kg/m2.

- Chronic HCV genotype 1b infection/with or without cirrhosis or HCV genotype 4
infection/without cirrhosis for at least 6 months prior to study screening.

- Subject has plasma HCV RNA level > 10,000 IU/mL at Screening

Exclusion Criteria:

- History of severe, life-threatening or other significant sensitivity to any drug.

- Females who are pregnant or breastfeeding.

- Recent history of drug or alcohol abuse that could preclude adherence to the
protocol.

- Positive test result for hepatitis B surface antigen or anti-Human Immunodeficiency
Virus (HIV) antibodies.